SOLVING THE KNOWLEDGE MANAGEMENT PUZZLE IN BIOPHARMA

whitePaper | July 21, 2022

The growing costs of the diabetes epidemic in the U.S. are staggering. Over 37 million Americans around 11% of the population now have diabetes, and according to a recent study, over 60 million Americans are expected to have the disease by 2060.

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

whitePaper | December 22, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies, the sooner a new treatment can be available for patients.

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.